Zacks Research Comments on Alnylam Pharmaceuticals, Inc.’s FY2026 Earnings (NASDAQ:ALNY)

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Research analysts at Zacks Research raised their FY2026 EPS estimates for shares of Alnylam Pharmaceuticals in a research report issued on Tuesday, September 24th. Zacks Research analyst A. Chakraborty now expects that the biopharmaceutical company will post earnings per share of $2.15 for the year, up from their prior forecast of $2.11. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.73) per share.

Other research analysts also recently issued research reports about the company. Barclays increased their target price on Alnylam Pharmaceuticals from $291.00 to $295.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. The Goldman Sachs Group raised shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the company from $198.00 to $370.00 in a research note on Friday, August 16th. HC Wainwright reiterated a “buy” rating and set a $400.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, August 30th. Royal Bank of Canada reiterated an “outperform” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, September 19th. Finally, Canaccord Genuity Group raised their price target on shares of Alnylam Pharmaceuticals from $357.00 to $366.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Seven equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $279.14.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $274.91 on Friday. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $287.55. The firm has a market capitalization of $34.77 billion, a PE ratio of -102.58 and a beta of 0.38. The stock’s 50 day moving average price is $263.00 and its 200 day moving average price is $203.01.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.61. The firm had revenue of $659.83 million for the quarter, compared to analyst estimates of $447.22 million. During the same period in the prior year, the business earned ($2.21) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 107.0% on a year-over-year basis.

Insider Buying and Selling

In other news, Director Dennis A. Ausiello sold 20,250 shares of the company’s stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total value of $5,305,500.00. Following the completion of the sale, the director now owns 136 shares of the company’s stock, valued at approximately $35,632. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Dennis A. Ausiello sold 20,250 shares of the business’s stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $262.00, for a total transaction of $5,305,500.00. Following the sale, the director now owns 136 shares of the company’s stock, valued at $35,632. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Yvonne Greenstreet sold 7,093 shares of Alnylam Pharmaceuticals stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $261.00, for a total value of $1,851,273.00. Following the completion of the sale, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at approximately $19,168,101. The disclosure for this sale can be found here. In the last ninety days, insiders sold 57,491 shares of company stock valued at $15,446,733. Company insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC raised its position in shares of Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 143 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the second quarter valued at about $26,000. Altitude Crest Partners Inc. purchased a new stake in Alnylam Pharmaceuticals in the first quarter valued at about $30,000. V Square Quantitative Management LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $52,000. Finally, Prestige Wealth Management Group LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 69.8% in the 1st quarter. Prestige Wealth Management Group LLC now owns 472 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 194 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.